Co-Founder & Chief Scientific Officer (CSO)
Dr. Tamaro Hudson is Co-Founder and Chief Scientific Officer of OncoVanta Therapeutics, where he leads the company’s scientific vision and translational oncology strategy. As an NIHfunded investigator and faculty member at Howard University, Dr. Hudson brings deep expertise in tumor biology, biomarker discovery, and the development of targeted cancer therapies. At OncoVanta, Dr. Hudson serves as Lead Principal Investigator for NIH STTR/SBIR initiatives, bridging academic research excellence with commercial innovation. His work focuses on advancing proof-of-concept studies and guiding preclinical strategy for TCR-based therapies that target mutant p53 neoantigens in solid tumors. Dr. Hudson’s leadership at the intersection of academia and biotechnology enables OncoVanta to integrate cutting-edge cancer biology with real-world therapeutic development.
